Rocket Pharmaceuticals explains lower dose behind Danon gene therapy restart at Meeting on the Mesa
CEO Gaurav Shah said a product enriched for full capsids drove the dose cut in the pivotal Danon trial, ahead of an investor webinar on updated Phase 1 data on October 6.


